• Terms of use

    1. Acceptance Your access to and use of this Site is subject to the following terms and conditions and all applicable laws. By accessing and browsing this Site, you accept, without limitation or qualification, these Terms and Conditions and acknowledge...

  • Privacy Policy

    Privacy Policy Effective: April 2020 This Privacy Policy describes the ways in which Novartis Singapore Pte Ltd; Novartis Asia Pacific Pharmaceutical Pte Ltd and Novartis Singapore Pharmaceutical Manufacturing Pte Ltd (referred here as “ Novartis ”, “ we...

  • Novartis General Privacy Notice for Healthcare Professional

    At Novartis, we strive to be transparent in all our interactions. From time to time, Novartis (Singapore) Pte. Ltd. (referred as "Novartis" or "we" or "us") solicits Personal Data from Healthcare Professional (“HCP”) with whom we intend to create and...

  • Talking Hearts S2

    The first season of Talking Hearts had featured a group of local cardiologists sharing their experiences in the management of heart failure. In season 2, we invite local cardiologists to share their thoughts on the evolving landscape in lipids management...

  • Quality of Life

    References Slamon DJ, Neven P, Chia S, et al. Overall Survival With Ribociclib Plus Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2020 Feb 6;382(6):514-524 Fasching PA, Esteva FJ, Pivot X, et al. Patient-reported outcomes in advanced breast cancer...

  • Webinar

    Latest Updates In April 2022, new heart failure (HF) guidelines has been released by three North American societies – ACC, AHA and HFSA. The guideline document has included both new and repurposed drug therapies that benefit across the ejection fraction...
×

Medical Information Request

×

Ask Speakers